Amesite Launches Census-Based Enterprise Tier for NurseMagic(TM) to Drive Revenue Growth and Meet Enterprise Demand, Significantly Expanding Total Addressable Market

Stock Information for Inozyme Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inozyme Pharma Inc.

Amesite Announces 69% QoQ Revenue Increase in Q2 2026 and Product Plans for Coming Months
Amesite Reports 63% Revenue Growth from NurseMagic(TM) Enterprise; Announces Launch of AI-Powered Government Form-Fill Automation to Reduce Reporting Burden
Amesite's HIPAA Compliant NurseMagic(TM) App Now Operates in 16 Languages - Expanding Access to AI-Powered Charting for Nearly 1 Million U.S. Nurses
Amesite Announces Quarterly Revenue Increase of 2.4x in 10-Q Filing
Amesite Announces Successful Launch of New, Higher-Priced Tier of Service in Response to B2B Demand
New Advances in Healthcare AI Could Unlock Billions in Market Opportunity
Amesite Announces NurseMagic(TM) Meets HIPAA Requirements for Individuals Users, in Addition to Enterprises
Amesite (Nasdaq: AMST) Anticipates Sales Growth Amid Shifting Trade Dynamics

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.